GlassScriptPhysician profile
Ana Vargas
NPI 1750748679
$2,019.10
in general payments reported to CMS, 2019-2025
17 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $590 · 2023: $907 · 2024: $378 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.85 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.61 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $214.43 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $132.30 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $114.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $108.90 | 2022 | |
| Scynexis, INC. | $100.14 | 2022 | |
| Medtronic, INC. | $91.12 | 2022 | |
| Abbvie INC. | $87.12 | 2023-2024 | |
| Shield Therapeutics INC | $82.36 | 2023 | Accrufer |
| Qiagen, LLC | $81.48 | 2023 | Quantiferon-Tb Gold Plus |
| Bayer Healthcare Pharmaceuticals INC. | $46.86 | 2022-2023 | |
| Pfizer INC. | $40.77 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $36.37 | 2022-2023 | Rexulti |
| Digestive Care, INC. | $30.12 | 2023 | Pertzye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $27.19 | 2024 | Affinity |
| Glaxosmithkline, LLC. | $21.97 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.